Personalis has extended its strategic collaboration with Tempus AI to broaden commercialization of the NeXT Personal minimal residual disease (MRD) assay into colorectal cancer, adding to prior indications including breast and lung cancers and immunotherapy monitoring. The exclusive deal now runs through 2029 with Tempus as Personalis’ commercial partner covering all four cancer types through 2028. Personalis’ ultra-sensitive liquid biopsy technology detects low levels of circulating tumor DNA, demonstrated in clinical data to enhance early detection and monitoring of colorectal and cervical cancers. CEO Chris Hall noted that Tempus’ extensive oncologist network in the U.S. will accelerate access to the assay, translating into timely and actionable treatment decisions for patients. The partnership aligns with growing interest in using MRD assays to improve cancer prognosis and guide adjuvant therapy.